Detalhe da pesquisa
1.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079938
2.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int
; 126(1): 73-82, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233107
3.
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
Eur Urol
; 79(5): 659-662, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654802
4.
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Eur Urol
; 79(5): 665-673, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33678522
5.
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Cancer Cell
; 38(6): 803-817.e4, 2020 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33157048
6.
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
Clin Cancer Res
; 26(11): 2506-2514, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32127394
7.
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Bladder Cancer
; 4(2): 227-238, 2018 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29732393
8.
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(12): 1941, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291359
9.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(6): 749-757, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867230